Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

MGF Igf-1-ec

IGF-1Ec, IGF-1Eb, Mechano-Growth Factor

Quick Stats
Studies 62
Trials 100
Not Yet Recruiting OBSERVATIONAL NCT06166797

Elucidating Growth Hormone Dynamics at Stages of Progressive Nonalcoholic Fatty Liver Disease

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The purpose of this study is to investigate relationships between the body's growth hormone "axis" and nonalcoholic fatty liver disease. The growth hormone "axis" includes the hormones growth hormone and insulin-like growth factor 1, and associated proteins. We hypothesize that there will be a relationship such that people with more advanced nonalcoholic fatty liver disease will have greater impairments in the growth hormone axis. There are no treatments associated with this research study.

Detailed Description

Several lines of existing research implicate activity of the GH/IGF-1 axis in the development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in humans. Careful phenotyping of GH dynamics in individuals with NAFLD and NASH is required for comprehensive understanding of the degree to which perturbations in the GH axis contribute to the pathogenesis of NAFLD/NASH. The purpose of this research is to comprehensively assess GH dynamics in individuals across the spectrum of NAFLD to determine associations between the GH/IGF-1 axis and stages of disease progression in NAFLD.

Primary Outcomes

Measure: peak growth hormone
TimeFrame: at baseline
Description: peak growth hormone level during standard 3-hour glucagon stimulation test

Trial Information

NCT ID

NCT06166797

Status

Not Yet Recruiting

Study Type

OBSERVATIONAL

Sponsor

Massachusetts General Hospital

Last Updated

December 15, 2025

Related Peptides